Wrapmanager Inc. Cuts Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Wrapmanager Inc. reduced its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 26.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 5,086 shares of the biopharmaceutical company’s stock after selling 1,853 shares during the period. Wrapmanager Inc.’s holdings in Halozyme Therapeutics were worth $291,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Verdence Capital Advisors LLC lifted its stake in Halozyme Therapeutics by 1.9% during the third quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock worth $757,000 after purchasing an additional 252 shares during the last quarter. GAMMA Investing LLC lifted its position in Halozyme Therapeutics by 96.6% in the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 254 shares during the last quarter. Fifth Third Bancorp boosted its stake in Halozyme Therapeutics by 2.4% in the second quarter. Fifth Third Bancorp now owns 11,206 shares of the biopharmaceutical company’s stock worth $587,000 after buying an additional 261 shares in the last quarter. Private Advisor Group LLC grew its position in Halozyme Therapeutics by 1.8% during the second quarter. Private Advisor Group LLC now owns 22,753 shares of the biopharmaceutical company’s stock valued at $1,191,000 after acquiring an additional 412 shares during the last quarter. Finally, Juncture Wealth Strategies LLC raised its stake in shares of Halozyme Therapeutics by 3.6% during the third quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company’s stock worth $690,000 after acquiring an additional 415 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $44.81 on Wednesday. The stock’s 50 day moving average is $55.42 and its 200 day moving average is $53.53. The company has a market capitalization of $5.70 billion, a P/E ratio of 14.84, a PEG ratio of 0.42 and a beta of 1.29. Halozyme Therapeutics, Inc. has a twelve month low of $33.15 and a twelve month high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Analysts Set New Price Targets

HALO has been the topic of several recent research reports. JMP Securities increased their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Wells Fargo & Company cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price objective for the company from $58.00 to $62.00 in a research note on Monday, October 7th. TD Cowen boosted their target price on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Benchmark reissued a “buy” rating and set a $60.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. Finally, Piper Sandler increased their price objective on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $61.11.

Insider Transactions at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total value of $532,600.00. Following the transaction, the senior vice president now owns 173,756 shares in the company, valued at $9,254,244.56. The trade was a 5.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 60,000 shares of company stock valued at $3,425,000. Insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.